Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 EmblemHealth Large Group ASO NRA Preferred Formulary (covered drugs list)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the list of covered outpatient prescription drugs, tiers, and common benefit restrictions (e.g., prior authorization, quantity limits, step therapy, specialty drug handling) for EmblemHealth Large Group ASO NRA Preferred members as of Apr 1, 2026.

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Large Group ASO NRA Preferred Formulary (covered drugs list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug line is annotated with 'PA' before dispensing to secure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Apr 1, 2026formulary effective/update date
    Home deliverymail-order option noted
    PA / QL / ST / LA / SPcommon requirements
    ~150+distinct line-items
    PA/QL/LA/SPrequirement flags

    Coverage and Formulary Scope

    General coverage

    Covered when listed on the formulary and plan benefit applies.

    Formulary coverage baseline: Drug appears on the plan formulary list and member's Certificate of Coverage allows payment for that drug form/tier

    Some drugs retain additional restrictions (PA, QL, ST, LA, SP) which must be met; absence of PA/QL/ST flags implies standard coverage per benefit

    Formulary coverage with PA/QL/SP requirements

    Coverage and utilization controls apply per drug as listed below when payer requirements are met.

    General formulary controls: Drugs are covered according to formulary tier but may require PA, QL, SP, LA as indicated for each product entry

    Provider must comply with specified prior authorization, quantity limits, and specialty pharmacy requirements for listed products

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Large Group ASO NRA Preferred Formulary (covered drugs list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug line is annotated with 'PA' before dispensing to secure coverage.
    SourceLink
    On This Page
    Coverage and Formulary ScopeFormulary Listings and Product CodesPrescriber Requirements, Authorizations, and Denial RisksStep Therapy and Initial Treatment RulesQuantity Limits by ProductSpecialty Pharmacy, Infusion, and Limited-Access SettingsPolicy Background and ScopeAbbreviations and TermsBiosimilars and Related Rules

    Formulary coverage entries

    Drugs listed are subject to formulary tiering and specified utilization controls (QL, ST, PA).

    Formulary entry: Each drug listed includes Drug Tier and, where applicable, Requirements/Limits such as QL, ST, PA.

    See individual drug lines for exact QL/ST/PA values

    Coverage stance for listed drugs

    Coverage and dispensing are governed by formulary tier plus any listed Requirement/Limits flags. Drugs with PA/QL/LA/SP require administrative steps.

    General coverage conditions: Drug is subject to the formulary tier and any Requirement/Limits (PA, QL, LA, SP, ACA) specified; where 'PA' is present prior authorization is required before coverage; where 'QL' is present quantity limits apply; 'SP' indicates specialty pharmacy handling; 'ACA' indicates ACA-related coverage mandates.

    From the item Requirement/Limits fields

    Listing a medicine in this formulary excerpt does not guarantee that the plan will pay for it. The document states that coverage depends on the member’s Certificate of Coverage and that ‘‘Not all drugs in this list are paid for by all drug benefit plans, so coverage is not guaranteed.’’ Providers and members should verify benefit details and any plan-specific requirements before dispensing or filling a prescription.

    This extract contains partial formulary listings and does not include explicit exclusions. The entries shown are a subset of the full Prescription Drug List and therefore do not by themselves represent a complete statement of non‑coverage.

    The segment is a formulary listing showing drug names, tiers, and utilization controls (for example, Quantity Limits and Step Therapy annotations). No detailed clinical medical‑necessity criteria or explicit exclusions are provided in these chunks; individual drugs are presented with their plan annotations (e.g., QL, ST, PA) which govern coverage conditions.

    Within the provided excerpt there are no explicit product‑level exclusions stated. Drug lines include Requirements/Limits flags (such as LA, PA, QL, SP) but do not list products as expressly excluded in these chunks.

    This portion of the formulary lists drug tiers and utilization controls but does not set out standalone clinical coverage rules or explicit exclusions. Entries show examples of Requirements/Limits such as PA, QL and LA that must be met for coverage; the extract itself does not provide full clinical criteria for authorization decisions.

    No explicit clinical exclusions are stated in the provided extract. The content focuses on the formulary entries (drug name, tier, and any Requirements/Limits) rather than on statements that certain therapies are not medically necessary.

    The excerpt does not contain explicit ‘‘not medically necessary’’ determinations. Coverage direction in these chunks is limited to formulary placement and annotations indicating administrative controls (e.g., PA, QL, ST, LA, SP); clinical non‑coverage language is not present here.

    The supplied extract does not include explicit statements labeling therapies as medically unnecessary. Instead, it shows drug lines with Requirements/Limits (for example, QL and ST) which prescribe administrative conditions for coverage rather than clinical denial language.

    No explicit ‘‘not medically necessary’’ language appears in these sections. The document excerpts presented list quantity limits, prior‑authorization flags, and tier assignments without accompanying statements that a product is not medically necessary.

    Formulary Listings and Product Codes

    Formulary drug listings (selected excerpts)mixedCovered
    amoxicillin (trihydrate) chew tab 125 mg, 250 mgDrug and strengths listed with Drug Tier = 3
    amoxicillin (trihydrate) cap 250 mg, 500 mgDrug and strengths listed with Drug Tier = 1
    amoxicillin (trihydrate) for susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlDrug and strengths listed with Drug Tier = 1
    amoxicillin (trihydrate) tab 500 mg, 875 mgDrug and strengths listed with Drug Tier = 1
    amoxicillin & k clavulanate for susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5mlDrug and strengths listed with Drug Tier = 1
    amoxicillin & k clavulanate for susp 600-42.9 mg/5ml (Augmentin es-600)Drug and strengths listed with Drug Tier = 1
    amoxicillin & k clavulanate tab er 12hr 1000-62.5 mgDrug and strengths listed with Drug Tier = 1
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgDrug and strengths listed with Drug Tier = 1
    AUGMENTIN - amoxicillin & k clavulanate for susp 125-31.25 mg/5mlBrand listed with Drug Tier = 3
    ampicillin cap 500 mgDrug and strengths listed with Drug Tier = 1
    1–10 of 35
    1/4
    Formulary product lines (partial)NDC | proprietary names
    tazemetostat hbr tab 200 mgTAZVERIK - tazemetostat hbr tab 200 mg
    temozolomide cap 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mgtemozolomide cap various strengths
    tepotinib hcl tab 225 mgTEPMETKO - tepotinib hcl tab 225 mg
    ivosidenib tab 250 mgTIBSOVO - ivosidenib tab 250 mg
    Formulary product lines (partial)NDC | proprietary names
    venetoclax tab 10 mg/50 mg/100 mgVENCLEXTA - venetoclax tablets and starter pack
    abemaciclib tab 50/100/150/200 mgVERZENIO - abemaciclib tablet strengths
    larotrectinib oral soln 20 mg/ml, caps 25 mg/100 mgVITRAKVI - larotrectinib formulations
    CorticosteroidsNDC | proprietary namesCovered
    dexamethasone soln/elixir/conc/tabDEXAMETHASONE - dexamethasone products listed
    methylprednisolone tab 2 mg/4 mg/8 mg/16 mg/32 mgMEDROL / methylprednisolone formulations
    prednisone oral soln and tabsPREDNISONE - various formulations
    Androgens / EstrogensNDC | proprietary names
    testosterone formulations (gels, injections, TD, auto-injector)Various testosterone products and limits
    estradiol and conjugated estrogens (multiple forms)Estrogens listed with QL or tier
    ContraceptivesNDC | proprietary names
    contraceptives (rings, IUDs, implants, oral)Multiple contraceptive products with ACA requirement or QL
    Product strengths listedmixed
    100 unit/mlTRESIBA FLEXTOUCH - insulin degludec soln pen-injector strength listed
    200 unit/mlTRESIBA FLEXTOUCH - insulin degludec soln pen-injector strength listed
    Thyroid product strengths/concentrationsmixed
    13 mcg - 200 mcgTIROSINT levothyroxine sodium capsule strengths listed
    13 mcg/ml - 200 mcg/mlTIROSINT-SOL levothyroxine sodium oral solution concentrations listed
    Selected rare disease therapy strengthsmixed
    0.4 mg, 0.56 mg, 1.2 mgVOXZOGO - vosoritide strengths listed
    Formulary drug strengths listedNDC-like/strength
    21-14-7 mg/24hrNICOTINE TRANSDERMAL SYST - nicotine td patch 24 hr kit 21-14-7 mg/24hr
    10 mg/ml (0.5 mg/spray)NICOTROL NS - nicotine nasal spray 10 mg/ml (0.5 mg/spray)
    125 mcg/0.5mlPLEGRIDY - peginterferon beta-1a soln auto-injector 125 mcg/0.5ml
    220 mgARCALYST - rilonacept for inj 220 mg
    80 mg/0.8mlADALIMUMAB-AATY CD/UC/HS - adalimumab-aaty auto-injector kit 80 mg/0.8ml
    40 mg/0.4mlADALIMUMAB-AATY 1-PEN KIT - adalimumab-aaty auto-injector kit 40 mg/0.4ml
    40 mg/0.4mlADALIMUMAB-ADAZ - adalimumab-adaz soln auto-injector 40 mg/0.4ml
    25 mg/0.5mlENBREL - etanercept subcutaneous soln prefilled syringe 25 mg/0.5ml
    80 mg/0.8mlHADLIMA - adalimumab-bwwd soln prefilled syringe 40 mg/0.4ml, 40 mg/0.8ml
    Home delivery recommended minimum duration
    Home delivery recommendationHome delivery may save members money if they refill monthly and expect to remain on the same drug for six months or longer.
    Delivery safety noteHome delivery is as safe as a local pharmacy; pharmacists check orders for accuracy and are available 24/7.
    When savings applySavings apply when refilling monthly and staying on the same medication for at least 6 months.
    Quantity limits examples
    Example QL — oral psychotropics/ADHD agentsQL examples shown include 240 tablets/30 days (e.g., dexmethylphenidate 2.5 mg), 1800 mls/30 days (dextroamphetamine solution), and 360 mls/30 days for some formulations.
    Example QL — stimulants and related agentsCommon quantity limits include 240 tablets/30 days and 60 capsules/30 days for select strengths/forms.
    Example QL — oncology and specialtyOther QL examples in document include 300 tablets/30 days and 120 tablets/30 days for selected agents.

    Prescriber Requirements, Authorizations, and Denial Risks

    Prior Authorization

    Obtain prior authorization when 'PA' is indicated

    Some drugs listed on the formulary require prior authorization (PA); the prescriber or patient must obtain PA approval before dispensing to secure coverage.

    Prior Authorization

    Submit PA or follow special handling for flagged products

    Products annotated with flags such as 'PA', 'ACA', 'LA', or 'SP' require the corresponding authorization, site‑of‑care handling, or specialty pharmacy routing shown on the formulary entry.

    • Follow 'ACA' entries for applicable ACA-covered vaccines/therapies.
    • Route LA/SP products through the specified site or specialty pharmacy per the formulary.
    Prior Authorization

    Submit PA and adhere to QL for specialty/oncology drugs

    Many antineoplastic and specialty agents are listed with Prior Authorization (PA) and Quantity Limits (QL); providers must submit PA requests and ensure dispensed quantities do not exceed the listed QL.

    • Examples include abiraterone (PA, QL) and multiple oncology agents with PA/QL/SP requirements.
    • Specialty routing (SP) is commonly required for these agents.
    Prior Authorization

    Obtain PA and follow QL/SP/LA for oncology agents

    Many oral oncology agents require prior authorization and have specified quantity limits and specialty pharmacy or limited‑access designations; obtain PA and follow QL and SP/LA instructions before dispensing.

    • Example: TAZVERIK — Requirements/Limits = LA, PA, QL (240 tablets/30 days), SP.
    • Check each oncology line for its exact PA/QL/LA/SP values.
    Prior Authorization

    Check for and submit PA when listed on product line

    Providers must check the formulary Requirements/Limits field and submit prior authorization when 'PA' appears on the product line; coverage may not be provided without PA.

    • Review per‑line Requirements/Limits prior to dispensing.
    • Do not assume coverage if PA is listed—obtain approval first.
    Prior Authorization

    Submit PA for select antidiabetics/weight agents

    Selected GLP‑1/antidiabetic and weight‑management agents (for example, MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) are PA‑restricted and subject to QL; submit PA and confirm QL before fill.

    • MOUNJARO entries show Requirements/Limits = PA, QL (e.g., 4 pens/180 days or 4 pens/28 days depending on strength).
    • OZEMPIC and RYBELSUS list PA and specific QL values.
    Prior Authorization

    Obtain PA and use specialty channels for endocrine agents

    Many specialty endocrine and high‑cost hormone/growth therapies (e.g., ACTHAR, GENOTROPIN, GALAFOLD) are designated LA/PA/SP and require prior authorization and specialty distribution where shown.

    • ACTHAR: Requirements/Limits = LA, PA, SP.
    • GENOTROPIN: Requirements/Limits = PA, SP; GALAFOLD: LA, PA, QL, SP.
    Prior Authorization

    Obtain PA for specialty/higher‑tier drugs before dispensing

    Specialty and higher‑tier drugs in this section commonly require prior authorization and may carry quantity limits or limited‑access designations; obtain PA before dispensing.

    • Examples include ADEMPAS (LA, PA, QL) and TYVASO (LA, PA, QL, SP).
    • Follow per‑product Requirements/Limits for PA and QL specifics.
    Prior Authorization

    Submit PA and use specialty pharmacy for selected biologics

    Many biologics and high‑cost oral specialty medications require prior authorization and specialty pharmacy processing; obtain PA and route prescriptions to the designated specialty channel when 'SP' is noted.

    • Examples: NUCALA, FASENRA PEN, TEZSPIRE, TRIKAFTA list LA, PA, QL, SP.
    • Follow the formulary's SP/LA instructions for distribution and site‑of‑care.
    Prior Authorization

    Submit PA for specialty/high‑cost products and follow LA/SP/QL

    Many specialty or high‑cost products are annotated with PA and may also have LA, SP, and quantity limits; providers must submit prior authorization and adhere to the listed limits and site‑of‑care rules.

    • Examples: GATTEX — Requirements/Limits = LA, PA, SP; VOWST — LA, PA, QL (12 capsules/365 days), SP.
    • Confirm PA, QL and any LA/SP routing prior to dispensing.
    Prior Authorization

    Obtain PA for listed tasimelteon products

    Certain products (for example, tasimelteon presentations) specifically require prior authorization before coverage; obtain PA as indicated on the formulary line.

    • Tasimelteon capsule 20 mg: Requirements/Limits = PA, QL (30 capsules/30 days).
    • Hetlioz oral suspension: Requirements/Limits = LA, PA, QL, SP.
    Prior Authorization

    Submit PA when 'PA' is listed to secure coverage

    Providers must submit prior authorization when 'PA' appears on a drug's Requirements/Limits line to obtain coverage for that product.

    • Interferon and other immunomodulators (e.g., AVONEX) list PA and QL—submit PA per line item.
    • If PA is required and not obtained, coverage may be denied.
    Prior Authorization

    PA required for drugs annotated 'PA' (submit supporting docs)

    Products annotated with 'PA' in the Requirements/Limits column (for example PLEGRIDY, REBIF and sodium oxybate) require prior authorization; submit supporting documentation with the PA request.

    • PLEGRIDY entries show LA, PA, QL and SP designations.
    • REBIF lines list PA and QL (e.g., 12 syringes/28 days); sodium oxybate lists LA, PA, QL.
    Denial Risk

    Missing PA can result in non‑coverage

    If you fail to obtain a required prior authorization, the plan may not cover the drug; obtain PA before dispensing to reduce the risk of non‑payment.

    Note

    Flags imply authorization/site/specialty requirements

    Formulary flags (PA, ACA, LA, SP, QL) imply administrative requirements—missing these approvals or failing to follow the flag instructions may trigger coverage denials.

    Note

    Check PA, QL, LA, SP controls per drug

    Requests may be subject to prior authorization, quantity limits, site‑of‑care review, and specialty pharmacy designation depending on the drug; check each entry and follow the listed controls.

    Denial Risk

    Denial risk if PA/QL/SP/LA requirements unmet

    Claims may be denied if required prior authorization is not obtained, quantity limits are exceeded, or specialty pharmacy/site‑of‑care requirements are not met; ensure PA, QL and SP/LA routing are satisfied.

    Denial Risk

    Denial risk for missing PA/LA/SP or exceeding QL

    Claims lacking required prior authorization, missing site‑of‑care approval for LA products, not routed through specialty pharmacy when SP is indicated, or exceeding QL may be denied.

    Denial Risk

    PA or QL absence/exceedance may trigger denial

    Drugs with PA or QL noted on the formulary may require PA approval or be subject to quantity limits; failure to obtain PA or dispensing beyond the QL can result in claim denial.

    Denial Risk

    Denial risk when PA/ST/SP/QL conditions unmet

    If PA, step therapy (ST), specialty pharmacy (SP), or quantity limits (QL) conditions listed for a drug are not met, the request or claim may be denied.

    Denial Risk

    Obtain PA and meet limits to avoid denials

    Requests for drugs listed with Requirements/Limits = PA, LA, QL, or SP may be denied if those conditions are not met; obtain PA, respect QL, and follow LA/SP instructions where present.

    Prior Authorization

    Obtain PA and follow SP/LA for specialty respiratory biologics

    Specialty respiratory biologics (for example FASENRA, NUCALA, TEZSPIRE) list LA/PA/QL/SP—obtain required authorizations and route via specialty pharmacy as indicated to ensure coverage.

    • FASENRA PEN: LA, PA, QL (1 pen/28 days), SP
    • NUCALA: LA, PA, QL (1–3 pens/syringes/28 days), SP
    Prior Authorization

    Obtain PA and meet LA/QL/SP for CF modulators

    CF modulators and related specialty agents (e.g., TRIKAFTA, ALYFTREK, KALYDECO) list LA, PA, QL and SP; absence of authorization, exceeding QL, or incorrect routing risks denial.

    Denial Risk

    Denial risk when PA/LA/QL/SP criteria are not met

    Coverage may be denied if required prior authorization, site‑of‑care review, specialty designation, or quantity‑limit conditions listed on product lines are not met; follow listed requirements exactly.

    Denial Risk

    Adhere to QL and ST to avoid denials

    If quantity limits or step therapy requirements are present for a product, failure to meet those limits or follow ST sequencing can result in denial or reduced coverage.

    • Examples with ST/QL: FETZIMA (QL 30 capsules/30 days, ST), FLUOXETINE DR (QL 4 capsules/28 days, ST).
    Prior Authorization

    PA required for tasimelteon products

    Prior authorization is required for the listed tasimelteon presentations (capsule and oral suspension); lack of PA may result in denial.

    Prior Authorization

    Submit PA for PA‑flagged items (e.g., Saxenda)

    Providers must obtain prior authorization for products annotated with 'PA' (examples include liraglutide (Saxenda) and other PA‑flagged items); failure to obtain PA may limit or deny coverage.

    Billing Rule

    Claims may be denied when QL is exceeded

    Claims exceeding specified Quantity Limits (QL) (for example QL 30 capsules/30 days or QL 60 tablets/30 days) may be denied unless prior authorization or exception is obtained.

    • Verify the per‑product QL (days and unit) before dispensing to avoid claim denial.
    Prior Authorization

    PA is required when listed in Requirements/Limits

    Drugs listed with 'PA' in the Requirements/Limits field require prior authorization before coverage; check each drug line and submit PA when shown to obtain payment.

    Documentation Required

    Submit PA and required documentation for PA/LA/QL/SP items

    When a drug entry includes PA, LA, QL, or SP, the provider must submit the applicable prior authorization and supporting documentation and adhere to quantity or site restrictions as specified.

    • For LA/SP products, route prescriptions through the designated specialty pharmacy or site-of-care program.
    • Provide medical necessity and prior‑treatment documentation for ST/PA reviews.
    Step Therapy

    Follow step therapy: document prior trials when 'ST' is indicated

    Step therapy (ST) is applied to selected products; providers must document prior trials of required agents per the formulary's ST annotation before coverage will be authorized for the next therapy.

    • Examples with ST: FETZIMA, FETZIMA titration pack, FLUOXETINE DR, FANAPT titration packs, RISPERIDONE ODT (some strengths).
    • Document prior agent use and treatment failure as part of the PA/ST submission when requested.
    Documentation Required

    Confirm PA/LA/SP even when ST not specified

    Some products are labeled with LA and SP but do not show explicit step‑therapy sequences in this extract; still confirm PA/LA/SP requirements and supply routing before dispensing.

    Billing Rule

    Route LA/SP products through specialty channels and confirm PA

    For products with LA and SP designations (for example certain dosing packs), ensure prescriptions are routed to the specialty channel and obtain any required site‑of‑care approvals per the formulary.

    • Palforzia packs show LA and SP—route per payer instructions.
    • If ST is not listed, still verify PA/LA/SP requirements before dispensing.
    Documentation Required

    Adhere to ST and site restrictions where noted (e.g., KERENDIA)

    Some agents are marked with ST or site restrictions (e.g., KERENDIA) — follow the ST/site designation and document required prior therapy or site‑of‑care details when requesting authorization.

    Note

    Check tier/QL for inhaled products; implied step edits may apply

    Tiering and quantity limits for inhaled combination products may imply preferred alternatives and step edits; check QL and tier before dispensing and follow any implied step edits in the benefit system.

    • BREO ELLIPTA and TRELEGY entries include QL values—verify prior authorization or step requirements if applicable.
    Step Therapy

    Follow ST sequences and include prior‑therapy documentation

    When step therapy is listed for a product (for example AUVELITY, FETZIMA titration, FLUOXETINE DR), follow the ST requirements and include documentation of prior therapy and clinical rationale with the authorization request.

    Step Therapy

    ST applies to selected CNS/psychiatric products—document prior trials

    Step therapy applies to selected psychiatric and CNS drugs (e.g., FETZIMA, FLUOXETINE DR, FANAPT titration packs, RISPERIDONE ODT strengths); providers must follow ST and document prior trials when requesting coverage.

    Step Therapy

    Follow ST for gabapentin formulations and HORIZANT

    Gabapentin formulations and HORIZANT are labeled 'ST' in the formulary; obtain any required prior trials documentation and follow the ST requirement before coverage.

    Billing Rule

    Route SP‑designated drugs through the specialty pharmacy

    Some specialty products carry 'SP' indicating they must be dispensed via a designated specialty pharmacy; route prescriptions accordingly and enroll the member in specialty programs if required.

    • Examples: many adalimumab biosimilars and interferon products list SP—use the specialty pharmacy channel.
    Note

    Interpret and act on formulary annotations (PA/QL/ST/LA/SP)

    Formulary entries include abbreviations (PA, QL, ST, LA, SP); providers must interpret these flags and take the administrative actions shown (e.g., submit PA, respect QL, route to SP) when submitting claims or prescriptions.

    Documentation Required

    Submit required documentation for flagged products

    When a product line includes PA, QL, ACA, LA, or SP flags, the provider must submit the appropriate authorization request and adhere to quantity and site/program requirements indicated on the formulary line.

    • Include supporting clinical documentation and prior‑therapy history where ST is indicated.
    Documentation Required

    Follow per‑line Requirements/Limits when submitting claims/PA

    Drug entries list specific Requirements/Limits such as PA, QL, LA and SP; providers must follow those instructions when submitting claims or prior authorization requests.

    Step Therapy and Initial Treatment Rules

    Step therapy (initial therapy) rules

    Step therapy (ST) must be followed where indicated on the formulary prior to coverage of the requested product.

    Step therapy applies when indicated: When a product line is annotated with 'ST', prescriber must document trial and inadequate response or intolerance to the required prior agent(s) per payer step therapy rules before coverage is approved.

    Specific step sequences and prior agents are defined in the payer's authorization system or product-specific policy; see the product Requirements/Limits for ST entries such as FETZIMA, FETZIMA titration pack, FLUOXETINE DR, FANAPT titration packs, RISPERIDONE ODT, gabapentin formulations and HORIZANT.

    Summary
    Step therapy (ST) may require trial of specified alternative drugs before coverage of another agent; follow the 'ST' annotation shown next to drug names.
    Summary
    No explicit step-therapy sequences or required prior agents are listed in this segment for the included products (entries show LA/SP but not ST sequences).
    Summary
    Some products list LA in addition to PA and QL (e.g., pemigatinib, PIQRAY, POMALYST) in their Requirements/Limits; specific step-therapy (ST) details are not enumerated in these lines.
    Summary
    Certain products include LA (site/limited access), PA, QL and SP flags (e.g., PALFORZIA entries show LA, SP; several oncology entries show LA/PA/QL/SP), but no explicit step edits are shown in these excerpts.
    Summary
    Some specialty antidiabetic agents (e.g., MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) are annotated with PA and QL and may be subject to step edits in the payer system, though specific step sequences are not listed here.
    Summary
    KERENDIA (finerenone) is listed in the formulary entries and noted in the brief as having an ST designation (ST/site indicated alongside QL/PA where applicable).
    Summary
    High‑cost agents such as PCSK9 inhibitors (example: REPATHA/evolocumab) are listed with quantity limits (QL) and may be subject to utilization management including step therapy in the payer system, although explicit ST steps are not provided here.
    Summary
    Tiered inhaled agents and combination inhalers (e.g., BREO ELLIPTA, BREZTRI, DULERA) have quantity limits and tier assignments that may imply preferred alternatives; explicit step-therapy rules are not stated in these excerpts.
    Product
    AUVELITY — dextromethorphan-bupropion
    FETZIMA — levomilnacipran (including titration pack)
    FLUOXETINE DR — fluoxetine delayed-release 90 mg
    Summary
    Step therapy is required for selected medications (examples in the formulary include AUVELITY, FANAPT titration packs, and certain strengths of risperidone ODT), but the specific prior agents or step sequences are not listed in these excerpts.
    Product
    Gabapentin (once-daily formulations — Gralise) — marked ST
    HORIZANT (gabapentin enacarbil) — marked ST
    Summary
    Multiple biologic and biosimilar products (e.g., adalimumab biosimilars) are flagged with PA and QL and carry specialty pharmacy (SP) designations; explicit step-therapy specifications are not provided in these chunks but administrative controls are implied.

    Quantity Limits by Product

    SUNLENCA tablet packs and tabs
    SUNLENCA tablet packs (4x300 mg)QL = 4 tablets/365 days (therapy pack 4 x 300 mg).
    SUNLENCA tablet packs (5x300 mg)QL = 5 tablets/365 days (therapy pack 5 x 300 mg).
    SUNLENCA single tabletsSUNLENCA tab 300 mg listed with QL (4 tablets/365 days) for some single-tab entries.
    SYMTUZA
    SYMTUZAQL = 30 tablets/30 days.
    TIVICAY 50 mg
    TIVICAY 50 mgQL = 60 tablets/30 days.
    VOSEVI
    VOSEVIRequirements/Limits = PA, QL (28 tablets/28 days), SP.
    YEZTUGO tablets
    YEZTUGO tabletsQL = 4 tablets/365 days; ACA and SP flags appear for some YEZTUGO presentations.
    VIREAD (tenofovir disoproxil fumarate) 300 mg
    VIREAD 300 mgQL = 30 tablets/30 days.
    abiraterone acetate
    abiraterone acetateRequirements/Limits = PA, QL (120 tablets/30 days for 250 mg; 60 tablets/30 days for 500 mg), SP.
    BRUKINSA
    BRUKINSARequirements/Limits = LA, PA, QL (120 capsules/30 days or 60 tablets/30 days depending on formulation), SP.
    IMBRUVICA (ibrutinib) oral suspension 70 mg/ml
    IMBRUVICA oral suspension 70 mg/mLMultiple formulation QLs: 90 capsules/30 days; alternatively 30 tablets/30 days or 216 mL/30 days (entries show multiple formulation limits).
    INQOVI (decitabine-cedazuridine)
    INQOVIQL = 5 tablets/28 days; Requirements/Limits include LA, PA, SP.
    KISQALI (ribociclib) 200 mg pack
    KISQALI 200 mg packQL = 21 tablets/28 days (200 mg pack).
    LENVIMA packs
    LENVIMA packsQL varies by pack: examples include QL 30–90 capsules/30 days depending on pack (10–90 capsule pack examples shown).
    RETEVMO (selpercatinib)
    RETEVMO (selpercatinib)Requirements/Limits = LA, PA, QL (60–90 tablets/30 days depending on strength), SP.
    VENCLEXTA STARTING PACK
    VENCLEXTA STARTING PACKQL = 1 pack/180 days; Requirements/Limits = LA, PA, SP.
    tazemetostat (TAZVERIK)
    tazemetostat (TAZVERIK)Requirements/Limits = LA, PA, QL (240 tablets/30 days), SP.
    venetoclax (VENCLEXTA)
    venetoclax (VENCLEXTA)Requirements/Limits = LA, PA, QL (60 tablets/30 days for select strengths); starting pack QL = 1 pack/180 days.
    larotrectinib oral soln
    larotrectinib oral solutionRequirements/Limits = LA, PA, QL (300 mls/30 days), SP.
    MOUNJARO
    MOUNJARO (tirzepatide)Requirements/Limits = PA, QL (4 pens/180 days for 2.5 mg pack; 4 pens/28 days for other strengths as listed).
    MOUNJARO (other strengths)
    MOUNJARO (other strengths)Requirements/Limits = PA, QL (4 pens/28 days for many maintenance strengths).
    OZEMPIC
    OZEMPICRequirements/Limits = PA, QL (examples: 1 pen/28 days or 3 pens/28 days depending on presentation).
    RYBELSUS
    RYBELSUSRequirements/Limits = PA, QL (30 tablets/180 days for 3 mg; 30 tablets/30 days for other strengths as listed).
    SOLIQUA, TRULICITY, TRIJARDY XR, etc.
    SOLIQUA / TRULICITY / TRIJARDY XR examplesQuantity limits vary by product — examples include 6 pens/30 days (SOLIQUA), 4 pens/28 days (TRULICITY), 2 pens/28 days (some TRULICITY strengths).
    Multiple insulin products
    Multiple insulin product examplesQL examples include 10 vials/30 days; 33 pens/30 days; 100 mL/30 days depending on product/formulation.
    JANUMET XR, JANUMET
    JANUMET XR / JANUMETRequirements/Limits = QL (60 tablets/30 days or 30 tablets/30 days as listed).
    TRESIBA FLEXTOUCH
    TRESIBA FLEXTOUCHQL = 33 pens/30 days.
    GALAFOLD
    GALAFOLDQL = 14 capsules/28 days; Requirements/Limits = LA, PA, SP.
    IMCIVREE
    IMCIVREEQL = 10 vials/30 days; Requirements/Limits = LA, PA, SP.
    VOXZOGO
    VOXZOGOQL = 30 vials/30 days; Requirements/Limits = LA, PA, SP.
    teriparatide (Forteo) or palopegteriparatide (YORVIPATH)
    teriparatide (Forteo) / YORVIPATHForteo: QL = 1 pen/28–30 days; YORVIPATH: QL = 2 pens/28 days (palopegteriparatide).
    ADEMPAS - riociguat tab
    ADEMPAS (riociguat)QL = 90 tablets/30 days; Requirements/Limits = LA, PA, SP.
    REPATHA - evolocumab prefilled syringe/auto-injector
    REPATHA (evolocumab)QL = 6 syringes/pens (6 syringes or pens) per 28 days.
    UPTRAVI - selexipag tab
    UPTRAVI (selexipag)QL = 60 tablets/30 days.
    TYVASO - treprostinil inhalation solution
    TYVASO (treprostinil inhalation solution)QL = 7 packages/28 days; Requirements/Limits = LA, PA, SP.
    CORLANOR - ivabradine oral solution
    CORLANOR oral solutionQL = 600 mls/30 days; Requirements/Limits include LA, PA.
    BREO ELLIPTA
    BREO ELLIPTAQL = 60 blisters/30 days for some strengths; other strengths may have different QL (1 inhaler/30 days) depending on strength.
    NUCALA (prefill syringe)
    NUCALA (prefill syringe)QL = 1 syringe/28 days (prefill syringe presentation); other presentations QL = 3 pens/28 days.
    NUCALA (other presentations)
    NUCALA (other presentations)QL = 3 pens/28 days for specified presentations.
    TRELEGY ELLIPTA
    TRELEGY ELLIPTAQL = 60 blisters/30 days for some strengths or QL = 1 inhaler/30 days depending on strength.
    VENTOLIN HFA
    VENTOLIN HFAQL = 2 inhalers/30 days.
    OFEV
    OFEV (nintedanib)QL = 60 capsules/30 days; Requirements/Limits = LA, PA, SP.
    CITRATE - ferric citrate tab 1 gm (210 mg ferric iron)
    CITRATE - ferric citrate 1 gQL = 360 tablets/30 days.
    FOSRENOL - lanthanum carbonate chew tabs and powder packs
    FOSRENOL examplesQL varies by strength: examples include 180 packs/30 days, 120 packs/30 days, or 270 tablets/30 days depending on formulation/strength.
    sevelamer carbonate/tab and related formulations
    sevelamer carbonate packet 0.8 gmQL = 510 packets/30 days.
    sevelamer carbonate packet 2.4 gmQL = 150 packets/30 days.
    sevelamer tablets examplesExamples include QL 510 tablets/30 days, QL 960 tablets/30 days, QL 480 tablets/30 days depending on presentation.
    OMVOH - mirikizumab presentations
    OMVOH (mirikizumab) presentationsQL = 1–2 pens or syringes/28 days depending on presentation; Requirements/Limits = LA, PA, SP.
    SKYRIZI - risankizumab presentations
    SKYRIZI (risankizumab)QL = 1 pen/cartridge/56 days depending on presentation; Requirements/Limits = PA, QL, SP.
    TREMFYA INDUCTION PACK FO
    TREMFYA INDUCTION PACKQL = 3 kits/180 days; Requirements/Limits = PA, QL, SP.
    VOWST - fecal microbiota spores
    VOWSTQL = 12 capsules/365 days; Requirements/Limits = LA, PA, SP.
    ZYMFENTRA - infliximab-dyyb kits
    ZYMFENTRA kitsQL = 2 pens/28 days or 2 syringes/28 days depending on kit; Requirements/Limits = LA, PA, SP.
    various oral psychotropic agents
    Oral psychotropic QL examplesDocument shows multiple QL examples such as bupropion QL 120 tablets/30 days; citalopram QL 120 tablets/30 days; duloxetine QL 180 capsules/30 days.
    escitalopram oxalate presentations
    escitalopram oxalate solution 5 mg/5 mlQL = 600 mls/30 days.
    escitalopram oxalate tab 5 mgQL = 120 tablets/30 days.
    venlafaxine hcl cap er 37.5 mg
    venlafaxine HCl cap ER 37.5 mgQL = 180 capsules/30 days.
    lurasidone hcl tab (20–120 mg)
    lurasidone (20–120 mg)QL = 30 tablets/30 days for most strengths; QL = 60 tablets/30 days for 80 mg strength.
    dexmethylphenidate and related stimulant examples
    dexmethylphenidate (Focalin) 2.5 mg tabQL = 240 tablets/30 days.
    dextroamphetamine oral solution 5 mg/5 mlQL = 1800 mls/30 days.
    liraglutide (Saxenda)
    liraglutide (Saxenda)Requirements/Limits = PA, QL (15 mls/30 days).
    WEGOVY auto-injector (1.7 mg/0.75ml, 2.4 mg/0.75ml)
    WEGOVY auto-injector (1.7 & 2.4 mg)QL = 4 pens/28 days for 1.7 mg & 2.4 mg presentations; other WEGOVY strengths QL = 8 pens/180 days as listed.
    WEGOVY auto-injector (other strengths)
    WEGOVY other strengthsRequirements/Limits = PA, QL (8 pens/180 days) for other strength presentations.
    ZEPBOUND (various strengths)
    ZEPBOUND (tirzepatide) examplesQL = 4 pens/28 days or 4 pens/180 days depending on strength; Requirements/Limits = PA, QL.
    PLEGRIDY
    PLEGRIDYQL = 2 pens/28 days or 2 syringes/28 days for some presentations; starter pack QL = 1 kit/180 days; Requirements/Limits = LA, PA, SP.
    sodium oxybate (Xyrem)
    sodium oxybate (Xyrem / XYWAV)QL = 540 mls/30 days; Requirements/Limits = LA, PA, SP.
    VYLEESI
    VYLEESIQL = 6 pens/30 days; Requirements/Limits = LA, PA, SP.
    WAINUA
    WAINUAQL = 1 pen/30 days; Requirements/Limits = LA, PA, SP.
    fentanyl td patch / morphine sulfate tab er
    fentanyl transdermal patchQL = 15 patches/30 days.
    morphine sulfate tab ERQL = 90 tablets/30 days for extended-release presentations.

    Specialty Pharmacy, Infusion, and Limited-Access Settings

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy Background and Scope

    Background: This document is a payer Prescription Drug List for EmblemHealth that identifies covered outpatient prescription drugs, their drug tiers, and plan‑level annotations such as PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy), LA (Limited Availability) and SP (Specialty Pharmacy). It is intended to guide prescribing and benefit expectations for members of the EmblemHealth Large Group ASO NRA Preferred plan. The formulary notes that coverage depends on the member’s Certificate of Coverage, that not all drugs listed are paid for by all plans, and that utilization controls shown in the Requirements/Limits field must be satisfied for coverage to be provided.

    Abbreviations and Terms

    PA — Prior Authorization
    PAPrior Authorization — the plan requires approval before filling the prescription.
    QL — Quantity Limit
    QLQuantity Limit — the plan limits the amount of drug that will be covered over a specified time period.
    ST — Step Therapy
    STStep Therapy — the plan may require trying specified alternative drugs first before covering another product.
    LA — Limited Availability
    LALimited Availability — the drug may only be obtainable at selected pharmacies or through limited distribution.
    SP — Specialty Drugs
    SPSpecialty Drugs — drugs that may require special handling, monitoring, or patient education and often specialty pharmacy dispensing.
    PA — Prior authorization (definition)
    PA (definition)Prior authorization — administrative requirement for approval before coverage.
    QL — Quantity limit (definition)
    QL (definition)Quantity limit — maximum allowed quantity in a specified time frame (e.g., 30 tablets/30 days).
    SP — Specialty (definition)
    SP (definition)Specialty — indicates specialty pharmacy handling or specialty drug designation.
    LA — LA/site designation
    LA/site designationLA/site designation indicates a site‑of‑care or prior approval requirement (limited availability).
    PA — Prior Authorization (payer)
    PA — payer authorizationPrior Authorization — payer authorization required before claim approval.
    QL — Quantity Limit (time period)
    QL — time‑based maximumQuantity Limit — maximum quantity allowed per specified time period (e.g., 30 tablets/30 days).
    SP — Specialty Pharmacy
    SP — specialty pharmacy requirementSpecialty Pharmacy — drug must be dispensed through a designated specialty pharmacy where indicated.
    LA — Limit/Access designation
    LA — limit/access shorthandLA — document shorthand indicating limited access or site‑of‑care restriction paired with PA/QL in entries.
    LA — Limited Availability
    LA meaningLA = Limited Availability; drug may be obtained only through specified channels.
    PA — Prior Authorization (shorthand)
    PA meaningPA = Prior Authorization required before coverage.
    QL — Quantity Limit (shorthand)
    QL meaningQL = Quantity Limit specifying allowed supply per time period (e.g., '1 inhaler/30 days', '3 pens/28 days').
    SP — Specialty Pharmacy (shorthand)
    SP meaningSP = Specialty Pharmacy required for dispensing of the listed item.
    QL — Quantity Limit (examples)
    QL (example format)Quantity Limit — maximum quantity allowed in the specified time period (examples in document: 30 tablets/30 days, 60 capsules/30 days).
    ST — Step Therapy (definition)
    ST — definitionStep Therapy — a requirement that one or more specified alternative treatments be tried and documented before coverage is authorized.
    PA — Formal prior authorization
    PA — formal approvalPrior Authorization — formal approval required prior to coverage for designated products.
    PA — Approval before coverage
    PA — approval before coveragePrior Authorization — approval required before coverage is granted for the listed drug.
    QL — Quantity Limit (period)
    QL — maximum per periodQuantity Limit — maximum amount permitted per time period (e.g., 30 capsules/30 days).
    SP — Special Program
    SP — special programSP = Special Program or specialty pharmacy management for certain high‑cost drugs.
    LA — Limited Access (note)
    LA — limited access noteLA = Limited Access — restricted distribution or additional criteria needed for coverage.
    PA — Prior Authorization (requirement)
    PA — authorization requiredPrior Authorization — authorization required before coverage for many listed specialty items.
    QL — Quantity Limit (time-bound)
    QL — time‑bound maxQuantity Limit — maximum quantity allowed per specified time period (e.g., per 28 or 30 days).
    LA — Limited Access (definition)
    LA — limited access (definition)Limited Access — access restrictions apply (often specialty distribution).
    SP — Specialty Pharmacy (dispensing)
    SP — specialty dispensingSpecialty Pharmacy — requires specialty pharmacy handling or distribution for designated drugs.
    ACA — Affordable Care Act
    ACAACA — Affordable Care Act (coverage or requirement driven by ACA preventive/smoking‑cessation mandates).

    Biosimilars and Related Rules

    Note